A ge-related macular degeneration (AMD) is a chronic progressive eye disease that affects the macular region of the retina. 1 Inflammation seems to be involved in the pathogenesis of AMD; recent studies have shown that systemic inflammation is also highly likely to be present. 4 In addition, few studies have suggested an association between AMD and systemic diseases, in which chronic inflammation also plays a crucial role.
5-7
Chronic myeloproliferative neoplasms (MPNs) are hematologic cancers characterized by clonal proliferation of 1 or more myeloid cell lineages. These neoplasms encompass essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPNs. 8 Myeloproliferative neoplasms are heterogeneous but closely related diseases, with different cellular, molecular, and cytogenetic abnormalities as well as clinical presentations. However, these diseases have overlapping cellular and molecular alterations, and all MPNs are characterized by reduced survival among patients.
9,10
The role of chronic systemic inflammation in patients with MPNs has recently been characterized; 11 patients can experience symptoms and concurrent diseases driven by inflammation 12,13 (eg, osteoporotic fractures, 14 kidney diseases, 15 and hematologic and nonhematologic cancers, 16 as well as autoimmune phenomena 17, 18 ). Studies have revealed that some inflammatory pathways seen in patients with MPNs are similar to pathways demonstrated in patients with AMD. In particular, complement activation and altered nuclear factor erythroid 2-related transcription signaling appear to be involved in both diseases, potentially linking MPNs and AMD. 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] We aimed to investigate the risk of AMD in patients with MPNs because this could have clinical relevance for these patients and, additionally, contribute to a better understanding of the inflammatory components in the pathogenesis of AMD. In Denmark, patients with visual problems usually contact community-based general ophthalmologists; if signs of neovascular AMD are present, patients are then referred to hospital-based specialized care. Because the Danish health care system is a tax-funded public system with equal access for the entire population, the referral for and diagnosis of AMD are identical for everyone. In hospitals, the diagnosis is made by specialists in medical retinal diseases supported by multimodal imaging, including optical coherence tomography and fluorescein angiography (with registry-based record keeping of the diagnosis codes). National treatment guidelines for antivascular endothelial growth factor (anti-VEGF) suggest an initial loading dose with 3 monthly injections of anti-VEGF followed by an as-needed regimen. 29 Because expenses pertaining to anti-VEGF treatment are reimbursed by government funds, neither the department nor the patient has any expenses related to treatment.
Methods

Study Design and Data Sources
We undertook a matched cohort study using populationbased nationwide registries. 
Patients and Controls
All patients 18 years of age or older, registered with a firstever inpatient or outpatient MPN diagnosis in the DNPR between January 1, 1994, and December 31, 2013, were included. Individuals with initial records of an MPN diagnosis but who subsequently had only recordings of "cytosis by other causes" (secondary polycythemia; code D75.1) were excluded before matching, which was done to avoid the inclusion of patients with incorrect MPN diagnoses. The index date was defined as the date of the first primary-listed diagnosis with essential thrombocythemia, polycythemia vera, myelofibrosis, or unclassifiable MPNs. For each patient, we selected 10 controls (unexposed to MPNs), matched by age (birth month and year) and sex. Controls had to be alive at the index date of their corresponding patient and were assigned with an identical index date. To ensure that only incident AMD events were used in the analysis, we excluded persons who had prior AMD. Because few patients with MPNs could present with blurred vision at diagnosis (caused by rheologic changes), coincidental diagnosis of asymptomatic AMD after ophthalmologic evaluation cannot be excluded. Thus, we also excluded events recorded until the first 30 days after the index date. Accordingly, we also excluded patients and controls who had less than 30 days of follow-up.
Outcomes
We used all incident AMD events recorded in the DNPR as the primary outcome measure. Because patients had been referred to highly specialized hospital departments for evaluation, we expect that most patients had neovascular AMD. However, because information on AMD staging is limited in the DNPR, the overall unspecific AMD code (H35.3) could be used regardless of stage (eg, for both intermediate-stage or latestage dry AMD, as well as for neovascular AMD). To address this limitation, we therefore performed a subset analysis, estimating the risk using specific codes that were assigned only to persons who had neovascular AMD. Follow-up began 30 days after the index date for all participants and continued until December 31, 2013, death, emigration, or an AMD diagnosis, whichever occurred first. Information on persons with AMD who received a diagnosis and/or were treated only by general ophthalmologists (and thus were not subsequently referred to hospitals) were not included because the diagnostic codes from these community-based general ophthalmology clinics are not reported to the DNPR.
Statistical Analysis
Statistical analysis was performed from April 1, 2015, to October 31, 2016. We calculated descriptive statistics and presented the results as frequencies or mean (SD) values. The rates of AMD were calculated for all patients with MPNs as well as separately for each MPN subtype. The rates were compared with the rates of the matched controls and expressed as events per 1000 person-years at risk with 95% CIs. We computed the absolute risk of AMD for patients and controls during the first year, first 3 years, first 6 years, and first 10 years after the index date. The Kaplan-Meier method was used to estimate the cumulative incidence of AMD. We used the Cox proportional hazards regression model for the time-to-event analyses and the hazard ratio (HR), subsequently comparing the incidence of AMD observed among the patients with the incidence of AMD in the controls. Because smoking is a known risk factor for AMD 32 and is suggested to be a risk factor for MPNs as well, 33 we used smoking-associated diagnoses in the DNPR as a proxy measure for smoking. We lacked detailed patient information, such as their smoking status and specific treatments, because of the registry-based study design.
We initially performed stratified analyses using the periods of 1994-2001, 2002-2006, and 2007-2013 and adjusted the final analysis for risk time in these predefined periods. This stratification was done since new treatments were introduced for neovascular AMD at Danish hospitals in 2002 (verteporfin) and 2007 (anti-VEGF). Thus, persons with AMD were more likely to be referred to hospitals (for evaluation and potential treatment) rather than to general ophthalmology clinics in the most recent periods because these new treatments were not administered outside hospitals. Hence, more AMD events were recorded in the DNPR in the most recent period, regardless of exposure to MPNs.
In addition, we also estimated the risk of specifically coded neovascular AMD in an analysis confined to individuals with risk times after 2006 (without prior neovascular AMD). This analysis was performed since anti-VEGF treatment was administered nationwide at hospitals thereafter, and all individuals potentially eligible for treatment were evaluated at hospitals regardless of whether they had attended general ophthalmology clinics or hospitals before. Thus, no underreporting of neovascular events (requiring anti-VEGF treatment) occurred within that period.
The proportional hazard assumption was tested in all the models, and all statistical analyses were performed using the SAS statistical software package, version 9.4 (SAS Institute Inc), and R, version 3.2.2 (R Foundation for Statistical Computing). P < .05 was considered significant.
Results
We identified 8323 persons who received a diagnosis of MPN and 83 200 individually matched controls. Of these, 365 patients and 5755 controls were excluded, including 222 patients with prior AMD and 143 patients with less than 30 days of follow-up. A higher percentage of patients with MPNs than controls had prior AMD (eTable 2 in the Supplement), and the odds ratio of prior AMD overall was 1.1 (95% CI, 1.0-1.3). As shown in Figure 1 , controls corresponding to the excluded patients were also excluded from the study to maintain matching. In the final analysis, we included 7958 patients with MPNs (4279 women [53.8%] and 3679 men [46.2%]), with a mean (SD) age of 66.4 (14.3) years at diagnosis. The baseline characteristics are shown in Table 1 , whereas the number of incident AMD events, according to the different periods and MPN subtypes, is shown in eTable 3 in the Supplement. During the study period, 234 patients with MPNs received a diagnosis of AMD, corresponding to a rate of 5.2 (95% CI, 4.6-5.9) per 1000 person-years at risk. The corresponding rate for the 77 445 controls was 4.3 (95% CI, 4.1-4.4). The rates across each MPN subtype and matched controls are shown in Table 2 . The mean (SD) time to AMD was 5.6 (4.7) years for patients with MPN and 6.3 (4.9) years for the controls, with mean (SD) ages at AMD diagnosis of 77.9 (8.8) years for patients with MPNs and 79.1 (8.0) years for the controls. Specific results for MPN subtypes are shown in Table 2 .
The absolute risk of AMD for patients with MPNs was 0.4% (95% CI, 0.2%-0.5%) during the first year, 0.9% (95% CI, 0.7%-1.2%) during the first 3 years, 1.7% (95% CI, 1.4%-2.0%) during the first 6 years, and 2.4% (95% CI, 2.1%-2.8%) during the first 10 years. The absolute risks of AMD for patients with MPNs and controls within each subtype are shown in Table 2 . The cumulative risk revealed that the absolute risk of AMD increased over time for the patients with MPNs as well as for the a For some patients, fewer than 10 controls could be matched owing to old age (4 patients had 5 controls, 2 patients had 6 controls, 2 patients had 9 controls, and 8315 patients had 10 controls). general population ( Figure 2 ). The risk was comparable for the patients with MPNs and their controls during the first few years, but the risk was higher for the patients with MPNs than for the controls hereafter. In addition, our analyses revealed that the risk of AMD was significantly increased in the most recent periods and that smoking-related diagnoses were associated with an increased risk ( Table 3 ). The crude HR of AMD for patients with MPNs vs controls was 1.3 (95% CI, 1.2-1.4), and the adjusted HR was 1.3 (95% CI, 1.1-1.5). The adjusted HRs for AMD were increased across the different MPN subtypes, with HRs of 1.2 (95% CI, 1.0-1.6) for essential thrombocythemia, 1.4 (95% CI, 1.2-1.7) for polycythemia vera, 1.7 (95% CI, 0.8-4.0) for myelofibrosis, and 1.5 (95% CI, 1.1-2.1) for unclassifiable MPNs.
There was a higher risk of neovascular AMD in the most recent period among patients with MPNs. Twenty patients with MPNs were recoded with specific-coded neovascular AMD (7 in essential thrombocythemia, 8 in polycythemia vera, 0 in myelofibrosis, and 5 in unclassifiable MPNs) after anti-VEGF treatment was introduced. The crude HR between patients with MPNs and controls was 1.3 (95% CI, 1.2-1.6), and the HR adjusted for smoking was 1.4 (95% CI, 1.2-1.6). Results for the MPN subtypes are shown in Table 3 .
Discussion
Using validated national registries, we included 7958 patients with essential thrombocythemia, polycythemia vera, myelofibrosis, or unclassifiable MPNs and 77 445 matched controls in a population-based observational study and found that patients with MPNs have an increased risk of AMD. To our knowledge, our study is the first to describe the risk of AMD in patients with MPNs, but we can only speculate on the causal pathways linking MPNs and AMD. The association may be explained in part by common inflammatory pathophysiological mechanisms because signs of chronic inflammation can be found in both patients with MPNs and patients with AMD. 4, 11 Thus, complement activation, increased oxidative stress responses, and elevated levels of inflammatory markers are common features in both diseases. 
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The etiological causes and the pathophysiology of MPNs are not fully known, but it is evident that the modulation of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway plays a central role. In the last decade, the understanding of the molecular pathogenesis has progressed markedly, and mutations in driver genes (JAK2 [GenBank NG_009904], CALR [GenBank NG_029662], and MPL [GenBank NG_007525]) that alter the signaling of the JAK-STAT pathway have been identified in patients with MPNs. 36 In addition, immune modulations that promote the proliferation of the malignant stem cell clone in the bone marrow, which in turn increases systemic inflammation, are involved. 11 Inflammation also plays a pivotal role in diseases that have previously been associated with MPNs, such as thrombosis, 37 atherosclerosis, 38 and autoimmune diseases. 39 The pathophysiology is also not entirely known for AMD, but well-recognized risk factors include a family history of AMD, older age, and smoking. 32, 40, 41 Immune mechanisms are also altered in patients with AMD, 42 and systemic inflammatory changes seem to be involved in the development and progression of the disease. 4 with concurrent chronic inflammation and immune deregulation might predispose some individuals to develop AMD.
Limitations
Despite the nationwide setting and complete follow-up, our study has some limitations. First, not all AMD events were included, and our results did not depict the incidence of AMD in Denmark because the DNPR does not capture information on individuals who are followed up solely at general ophthalmology clinics. However, since new AMD treatments, which are administered exclusively at hospitals, were introduced for patients with neovascular AMD, and all patients were mandatorily 
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Research Original Investigation AMD in Patients With Chronic Myeloproliferative Neoplasms referred for treatment evaluation at hospitals, accordingly, we expect that almost all neovascular AMD events in the most recent periods have been included in our study. Second, because detailed patient-specific information was not available in our registry data, we could not validate the diagnoses or include variables such as smoking status and administrated MPN treatments (eg, phlebotomy, aspirin, or cytoreductive treatment). Distinguishing between different MPNs at diagnosis can be difficult in clinical practice 47 ;
hence, we cannot exclude the potential misclassification of patients across the MPN subtypes. This possibility implies some limitations in interpreting the MPN subtype results. However, the diagnostic codes for hematologic cancers have high positive predictive values in the DNPR. 48 In our study, the influence of smoking was controlled using proxy measures, but residual confounding by smoking cannot be excluded. Moreover, because an association between aspirin use and the risk of AMD has been proposed, 49 ,50 the use of aspirin could be a confounding factor in our study, as patients with MPNs are regularly treated with aspirin. However, a meta-analysis based on 10 studies, which included 171 729 individuals, found that aspirin use was not associated with AMD. 51 Because both observational studies show opposing results regarding the association between aspirin use and AMD, and because experimental results are lacking, the evidence of an association is sparse. As suggested by others, 49, 52 we speculate whether the previously reported link between AMD and aspirin use is caused by confounding by indication-that is, that the underlying indication for aspirin treatment may increase the risk of AMD. Third, vascular events can occur in patients with MPNs, 53, 54 and ophthalmic symptoms such as blurred vision and scintillating scotomas due to microcirculatory disturbances and transitory ischemia in the retinal vessels have been reported. 55 Because patients with MPNs may present with blurred vision at diagnosis (which often resolves after the initiation of MPNspecific treatments such as phlebotomy, low-dose aspirin, and/or cytoreductive therapy), [56] [57] [58] more of the patients than the controls may have had ophthalmologic evaluations. This possibility could have led to the coincidental finding of AMD in few patients with MPNs (eg, asymptomatic intermediatestage AMD). However, we found only a few recorded AMD events in the month before or after the MPNs were diagnosed, and we minimized this bias by commencing follow-up after 30 days. We also found a higher prevalence of AMD at diagnosis, which indicates that the association between MPNs and AMD is not merely caused by referrals for ophthalmologic evaluation after the patients received a diagnosis of MPN. This finding strengthens the interpretation of our results, which suggests that MPNs are biologically associated with AMD, likely already at the time of diagnosis. Further substantiating our hypothesis, we found an increased risk of neovascular AMD in patients with MPNs after anti-VEGF treatment was introduced at hospitals nationwide-an era in which all neovascular events were recorded in the DNPR, irrespective of MPN exposure and whether persons had first attended general ophthalmology clinics or hospitals (some patients with late-stage AMD would likely have been followed up solely at general ophthalmology clinics before).
Conclusions
We find that patients with MPNs are at an increased risk for AMD when compared with age-and sex-matched controls from the general population. The association may possibly be explained by systemic inflammation. Our findings support that systemic changes may be involved in the development of AMD, but additional studies are needed to examine the underlying causal association. the incidence of neovascular age-related macular degeneration (AMD) among a population of Danish patients with these tumors. 1 Using an ageand sex-matched retrospective cohort study design, they compared the risk of developing AMD in patients with MPN with the risk for the general population. The risk of developing AMD was increased for patients with MPN, with an adjusted hazard ratio of 1.3 (95% CI, 1.1-1.5), and risk increased in all MPN subtypes (essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable).
To our knowledge, this study is the first to examine AMD risk among patients with MPN and notably uses a validated population-based registry. This national health database was linked with the Danish Civil Registration System, so the potential for bias was reduced because follow-up statuses (eg, date of death, emigration) could be obtained for the entire study sample. Because the study was observational, residual or unmeasured confounders could not be ruled out. However, the authors limited these by matching based on age and sex, factors known to affect AMD status. Uncontrolled confounding, along with possible selection biases, make observational studies of this type useful for generating hypotheses, but not for demonstrating causes and effects.
This interesting study about AMD associations with systemic inflammation was developed by authors who were working in a health care system that made it possible to answer such questions because of how intravitreal injections 
